Oehler Josephine B, Rajapaksha Weranga, Albrecht Hugo
College of Medicine and Dentistry, James Cook University, Townsville, QLD 4810, Australia.
Biomedical Sciences and Molecular Biology, College of Public Health, Medical & Vet Sciences, James Cook University, Townsville, QLD 4810, Australia.
J Pers Med. 2024 Jul 4;14(7):723. doi: 10.3390/jpm14070723.
Breast cancer remains the most prevalent cancer among women worldwide, driving the urgent need for innovative approaches to diagnosis and treatment. This review highlights the pivotal role of nanoparticles in revolutionizing breast cancer management through advancements of interconnected approaches including targeted therapy, imaging, and personalized medicine. Nanoparticles, with their unique physicochemical properties, have shown significant promise in addressing current treatment limitations such as drug resistance and nonspecific systemic distribution. Applications range from enhancing drug delivery systems for targeted and sustained release to developing innovative diagnostic tools for early and precise detection of metastases. Moreover, the integration of nanoparticles into photothermal therapy and their synergistic use with existing treatments, such as immunotherapy, illustrate their transformative potential in cancer care. However, the journey towards clinical adoption is fraught with challenges, including the chemical feasibility, biodistribution, efficacy, safety concerns, scalability, and regulatory hurdles. This review delves into the current state of nanoparticle research, their applications in breast cancer therapy and diagnosis, and the obstacles that must be overcome for clinical integration.
乳腺癌仍然是全球女性中最常见的癌症,这推动了对创新诊断和治疗方法的迫切需求。本综述强调了纳米颗粒在通过包括靶向治疗、成像和个性化医疗在内的相互关联方法的进步来彻底改变乳腺癌管理方面的关键作用。纳米颗粒具有独特的物理化学性质,在解决当前治疗局限性(如耐药性和非特异性全身分布)方面显示出巨大潜力。其应用范围从增强用于靶向和持续释放的药物递送系统到开发用于早期和精确检测转移灶的创新诊断工具。此外,将纳米颗粒整合到光热疗法中以及它们与现有治疗方法(如免疫疗法)的协同使用,都说明了它们在癌症治疗中的变革潜力。然而,走向临床应用的道路充满挑战,包括化学可行性、生物分布、疗效、安全性问题、可扩展性和监管障碍。本综述深入探讨了纳米颗粒研究的现状、它们在乳腺癌治疗和诊断中的应用以及临床整合必须克服的障碍。
J Trace Elem Med Biol. 2024-12
Molecules. 2023-6-30
Int J Pharm. 2024-9-5
Crit Rev Ther Drug Carrier Syst. 2022
Drug Deliv Transl Res. 2025-5-7
Biomimetics (Basel). 2025-1-3
Naunyn Schmiedebergs Arch Pharmacol. 2025-3
ACS Biomater Sci Eng. 2024-6-10
Adv Colloid Interface Sci. 2024-7
Naunyn Schmiedebergs Arch Pharmacol. 2024-9
Int J Mol Sci. 2024-4-5